IN2014MN02271A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02271A IN2014MN02271A IN2271MUN2014A IN2014MN02271A IN 2014MN02271 A IN2014MN02271 A IN 2014MN02271A IN 2271MUN2014 A IN2271MUN2014 A IN 2271MUN2014A IN 2014MN02271 A IN2014MN02271 A IN 2014MN02271A
- Authority
- IN
- India
- Prior art keywords
- inodilator
- converting enzyme
- enzyme inhibitor
- angiotensin converting
- formulation
- Prior art date
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 abstract 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902062A AU2012902062A0 (en) | 2012-05-18 | Liquid Formulation | |
| PCT/AU2013/000522 WO2013170317A1 (en) | 2012-05-18 | 2013-05-17 | Liquid formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02271A true IN2014MN02271A (de) | 2015-07-24 |
Family
ID=49582909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2271MUN2014 IN2014MN02271A (de) | 2012-05-18 | 2013-05-17 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9808529B2 (de) |
| EP (2) | EP3682902A1 (de) |
| JP (2) | JP2015516441A (de) |
| KR (1) | KR102041654B1 (de) |
| CN (2) | CN104619345A (de) |
| AU (1) | AU2013262438B2 (de) |
| BR (1) | BR112014028602B1 (de) |
| CA (1) | CA2873502C (de) |
| CL (1) | CL2014003121A1 (de) |
| CO (1) | CO7160059A2 (de) |
| HK (1) | HK1208372A1 (de) |
| IN (1) | IN2014MN02271A (de) |
| MX (1) | MX369832B (de) |
| NZ (2) | NZ724002A (de) |
| RU (1) | RU2640023C2 (de) |
| SG (3) | SG10201609364QA (de) |
| WO (1) | WO2013170317A1 (de) |
| ZA (1) | ZA201409269B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (de) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern |
| EP1920785A1 (de) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat |
| EP2825159B1 (de) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmazeutische tablettenformulierung für die veterinärmedizinische branche, herstellungsverfahren und verwendung dafür |
| JP2015516441A (ja) | 2012-05-18 | 2015-06-11 | ルオダ ファーマ ピーティーワイ リミテッド | 液体配合剤 |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| ES2860526T3 (es) | 2013-07-19 | 2021-10-05 | Boehringer Ingelheim Vetmedica Gmbh | Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida |
| PL2925305T3 (pl) * | 2013-12-04 | 2017-07-31 | Boehringer Ingelheim Vetmedica Gmbh | Ulepszone kompozycje farmaceutyczne pimobendanu |
| CN104161756B (zh) * | 2014-06-13 | 2017-02-01 | 河北智同医药控股集团有限公司 | 一种盐酸奥普力农注射液组合物 |
| US10350223B2 (en) | 2015-03-03 | 2019-07-16 | Richard W. Yee | Compositions and methods for treating ocular diseases |
| CN105029678A (zh) * | 2015-07-24 | 2015-11-11 | 广东中烟工业有限责任公司 | 一种烟草复合添加剂及其应用 |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CN106729723A (zh) * | 2016-11-21 | 2017-05-31 | 青岛农业大学 | 一种含匹莫苯丹的药物组合物及其制备方法 |
| BR112019021344A2 (pt) * | 2017-04-11 | 2020-06-16 | Ceva Sante Animale | Método para o tratamento de doença cardíaca em mamíferos |
| US10954115B2 (en) * | 2017-12-18 | 2021-03-23 | Maxum Enterprises, Llc | System and method for delivering fuel |
| FR3077984B1 (fr) * | 2018-02-16 | 2020-02-21 | Vetoquinol Sa | Composition multiusage de torasemide |
| CA3128033A1 (en) | 2019-01-31 | 2020-08-06 | Scpharmaceuticals Inc. | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| CN111803468B (zh) * | 2020-06-23 | 2022-12-23 | 黑龙江天龙药业有限公司 | 一种靶向、缓释、成膜抑制病毒、细菌的鼻腔喷膜剂及其制备方法 |
| KR102663470B1 (ko) | 2023-03-16 | 2024-05-10 | 주식회사 케어사이드 | 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제 |
| CN117538462B (zh) * | 2024-01-10 | 2024-03-26 | 地奥集团成都药业股份有限公司 | 一种氨氯地平贝那普利胶囊有关物质的检测方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05262650A (ja) | 1992-03-18 | 1993-10-12 | Meiji Seika Kaisha Ltd | 安定な注射用組成物 |
| IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| GB9717444D0 (en) * | 1997-08-19 | 1997-10-22 | Glaxo Group Ltd | Pharmaceutical composition |
| FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
| KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6706563B2 (en) | 2002-04-10 | 2004-03-16 | St Assembly Test Services Pte Ltd | Heat spreader interconnect methodology for thermally enhanced PBGA packages |
| EP1605916A4 (de) | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | Lösungsmittelsystem eines kaum löslichen arzneimittels mit verbesserter elutionsrate |
| HUP0300985A2 (hu) * | 2003-04-15 | 2005-07-28 | SynoSens Kutató és Fejlesztő Kft. | Megnövelt hatásszélességű gyógyászati készítmény |
| US9259390B2 (en) * | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| EP1579862A1 (de) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US20060099230A1 (en) | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
| EP1848424B1 (de) * | 2005-01-31 | 2017-04-05 | Mylan Laboratories, Inc | Pharmazeutische zusammensetzung enthaltend hydroxyliertes nebivolol |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CA2630458C (en) * | 2005-12-06 | 2014-10-28 | Wyeth | Benzimidazole non-aqueous compositions |
| JP4572300B2 (ja) | 2006-01-19 | 2010-11-04 | トーアエイヨー株式会社 | ピモベンダン経口投与製剤 |
| KR20070076769A (ko) * | 2006-01-20 | 2007-07-25 | 일양약품주식회사 | 암로디핀의 주사용 조성물 및 그의 제조방법 |
| EP1908469A1 (de) * | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen |
| JP2010514778A (ja) | 2006-12-28 | 2010-05-06 | オリオン コーポレーション | 非経口投与のためのレボシメンダン製剤 |
| WO2009061529A1 (en) | 2007-11-06 | 2009-05-14 | Tap Pharmaceutical Products, Inc. | (+)-enantiomer of 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole and processing method eor preparing the same |
| US20090270356A1 (en) * | 2008-04-28 | 2009-10-29 | Ceva Sante Animale Sa | Compositions and treatments of heart failure in non-human mammal animals |
| AU2010201490C1 (en) * | 2009-04-15 | 2014-07-24 | Zoetis Services Llc | Anthelmintic formulation |
| JP2011006380A (ja) | 2009-05-22 | 2011-01-13 | Mochida Pharmaceut Co Ltd | ω３脂肪酸の乳化組成物 |
| NL2006622C2 (en) * | 2011-04-18 | 2012-10-22 | Eurovet Animal Health B V | Use of a composition comprising torasemide. |
| JP2015516441A (ja) | 2012-05-18 | 2015-06-11 | ルオダ ファーマ ピーティーワイ リミテッド | 液体配合剤 |
-
2013
- 2013-05-17 JP JP2015511866A patent/JP2015516441A/ja active Pending
- 2013-05-17 WO PCT/AU2013/000522 patent/WO2013170317A1/en active Application Filing
- 2013-05-17 CN CN201380038290.2A patent/CN104619345A/zh active Pending
- 2013-05-17 AU AU2013262438A patent/AU2013262438B2/en active Active
- 2013-05-17 MX MX2014013871A patent/MX369832B/es active IP Right Grant
- 2013-05-17 EP EP20160396.6A patent/EP3682902A1/de active Pending
- 2013-05-17 IN IN2271MUN2014 patent/IN2014MN02271A/en unknown
- 2013-05-17 CN CN201811478216.3A patent/CN109568253B/zh active Active
- 2013-05-17 SG SG10201609364QA patent/SG10201609364QA/en unknown
- 2013-05-17 NZ NZ724002A patent/NZ724002A/en unknown
- 2013-05-17 SG SG11201407200TA patent/SG11201407200TA/en unknown
- 2013-05-17 CA CA2873502A patent/CA2873502C/en active Active
- 2013-05-17 EP EP13791455.2A patent/EP2849792B1/de active Active
- 2013-05-17 KR KR1020147035546A patent/KR102041654B1/ko active IP Right Grant
- 2013-05-17 NZ NZ701609A patent/NZ701609A/en unknown
- 2013-05-17 SG SG10201703789QA patent/SG10201703789QA/en unknown
- 2013-05-17 BR BR112014028602-7A patent/BR112014028602B1/pt active IP Right Grant
- 2013-05-17 RU RU2014145136A patent/RU2640023C2/ru active
- 2013-05-17 US US14/401,943 patent/US9808529B2/en active Active
-
2014
- 2014-11-17 CL CL2014003121A patent/CL2014003121A1/es unknown
- 2014-12-17 ZA ZA2014/09269A patent/ZA201409269B/en unknown
- 2014-12-17 CO CO14277303A patent/CO7160059A2/es unknown
-
2015
- 2015-09-18 HK HK15109160.8A patent/HK1208372A1/xx unknown
-
2016
- 2016-11-10 JP JP2016219381A patent/JP6448001B2/ja active Active
-
2017
- 2017-10-05 US US15/725,798 patent/US10413610B2/en active Active
-
2019
- 2019-08-16 US US16/542,518 patent/US11357855B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02271A (de) | ||
| HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
| HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| EA201500362A1 (ru) | Ингибиторы rho-киназы | |
| BR112015011830A2 (pt) | compostos e seus métodos de utilização | |
| UA118177C2 (uk) | Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну | |
| MX352926B (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| EA201290822A1 (ru) | Триазолоны в качестве ингибиторов синтазы жирных кислот | |
| EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
| HK1212628A1 (zh) | 用於抑制炎症的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑 | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX2014015039A (es) | Inhibidores de fbx03. | |
| EA201270728A1 (ru) | Пуриновые соединения | |
| PH12016500497A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| MX359181B (es) | Hidrolizado de colágeno y uso del mismo. | |
| IN2014DN00254A (de) | ||
| MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| EA201790537A1 (ru) | Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира | |
| IT1397473B1 (it) | Apparecchio portatile di elettrostimolazione del corpo umano |